Is Apimeds Pharmaceuticals US, Inc (APUS) a Buy, Sell, or Hold?
AMEX : APUS
Apimeds Pharmaceuticals US, Inc
$0.66 USD
$0.01 (0.76%)
- Volume
- 27.89K
- Average Volume
- 189.45K
- Market Capitalization
- $830.02K
- P/E Ratio
- -0.10
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $40.31
- Year Low
- $0.62
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.90
| Source | Headline |
|---|---|
|
For Second Straight Year, American Public University System (APUS) Earns Great Place to Work® Certification
Recognition Reflects Dedication, Collaboration, and Purpose-Driven Culture thatEmpower University Employees to Make Last Impacts on Global Students CHARLES TOWN, W.Va., June 8, 2026 /PRNewswire/ -- American Public University System (APUS) has again been certified as a Great Place to Work® , a recognition earned entirely through positive employee feedback. prnewswire.com - 2026-06-08 09:00:00 |
|
Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program
MATAWAN, N.J. & LA JOLLA, Calif.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) today announced a comprehensive settlement with Inscobee Inc. and Apimeds Inc. (the “Inscobee Parties”), resolving all outstanding disputes arising from the APUS' December 1, 2025, merger with MindWave Innovations Inc. The settlement clears the path for completion of the merger transactions, effectuation of the Company's previously disclosed $100 million PIPE financing, and the advancement. businesswire.com - 2026-05-05 14:07:00 |
|
APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, April 26, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Apimeds Pharmaceuticals US, Inc. ("Apimeds" or "the Company") (NYSE American: APUS) for violations of the securities laws. globenewswire.com - 2026-04-26 20:12:11 |
|
APUS Investors Have Opportunity to Join Apimeds Pharmaceuticals US, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, April 26, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Apimeds Pharmaceuticals US, Inc. (“Apimeds” or “the Company”) (NYSE American: APUS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. globenewswire.com - 2026-04-26 20:12:00 |
